{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:04:45Z","timestamp":1782601485542,"version":"3.54.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.tripleo.2011.06.023","type":"journal-article","created":{"date-parts":[[2012,1,3]],"date-time":"2012-01-03T02:14:44Z","timestamp":1325556884000},"page":"e1-e3","source":"Crossref","is-referenced-by-count":100,"title":["Sunitinib related osteonecrosis of jaw: a case report"],"prefix":"10.1016","volume":"113","author":[{"given":"Yoram","family":"Fleissig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tripleo.2011.06.023_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0278-2391(83)90294-X","article-title":"Osteoradionecrosis: a new concept of its pathophysiology","volume":"41","author":"Marx","year":"1983","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2011.06.023_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1754-4505.2002.tb01178.x","article-title":"Osteonecrosis of the maxilla as a complication to chemotherapy: a case report","volume":"22","author":"Sung","year":"2002","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.tripleo.2011.06.023_bib3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJM199704033361406","article-title":"Osteomyelitis","volume":"336","author":"Lew","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.tripleo.2011.06.023_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2011.06.023_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ctrv.2010.08.005","article-title":"Sunitinib for the treatment of metastatic renal cell carcinoma","volume":"37","author":"Oudard","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.tripleo.2011.06.023_bib6","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/1535-7163.MCT-05-0333","article-title":"SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity","volume":"5","author":"Patyna","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.tripleo.2011.06.023_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2011.06.023_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.tripleo.2011.06.023_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.tripleo.2011.06.023_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.tripleo.2011.06.023_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.tripleo.2011.06.023_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.tripleo.2011.06.023_bib13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","article-title":"Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?","volume":"20","author":"Ayllon","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tripleo.2011.06.023_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2011.06.023_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.tripleo.2011.06.023_bib16","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tripleo.2011.06.023_bib17","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.4317\/medoral.16.e137","article-title":"Maxillary osteonecrosis associated to antiangiogenic drugs","volume":"16","author":"Salort-Llorca","year":"2011","journal-title":"Med Oral Patol Oral Cir Bucal"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210411004240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210411004240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T09:24:06Z","timestamp":1543310646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079210411004240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1079210411004240"],"URL":"https:\/\/doi.org\/10.1016\/j.tripleo.2011.06.023","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}